4-(2,3-epoxypropoxy)-1H-indole-2-carboxamide | 62119-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(2,3-epoxypropoxy)-1H-indole-2-carboxamide
• 英文别名: 4-(2,3-epoxypropoxy)-2-carbamoyl-indole；4-glycidyloxy-1H-indole-2-carboxamide；4-glycidyloxy-2-indolecarboxamide；4-(-2-Oxiranylmethoxy)-2-indolecarboxamide；(2S)-4-glycidyloxy-2-indolecarboxamide；1H-Indole-2-carboxamide, 4-(oxiranylmethoxy)-；4-(oxiran-2-ylmethoxy)-1H-indole-2-carboxamide
• CAS: 62119-49-7
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: PPFALTLMNHVYKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2,3-epoxypropoxy)-1H-indole-2-carboxamide 生成 4-(3-(4-((4-Difluoromethoxyphenyl)phenylmethyl)piperazin-1-yl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile
  参考文献：
  名称：

  STENZEL, WOLFGANG;ARMAH, BEN;BEUTTLER, THOMAS

  摘要：

  DOI：

文献信息

• Indole derivatives for the treatment of depression and anxiety
  申请人：——

  公开号：US20040006229A1

  公开（公告）日：2004-01-08

  The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 1

  本发明提供了以下化合物的公式（I）：这些化合物对治疗抑郁症、焦虑症，并缓解因戒烟或部分戒烟引起的症状非常有用。
• Phenoxypropylamine compounds
  申请人：——

  公开号：US20020111358A1

  公开（公告）日：2002-08-15

  The present invention relates to a phenoxypropylamine compound of the formula (I) 1 wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT 1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.

  本发明涉及一种公式（I）中的苯氧丙胺化合物： 1 其中每个符号如说明书中所定义，其光学活性化合物或其药物可接受的盐及水合物，同时显示出对5-HT 1A 受体的选择性亲和力和拮抗活性，以及5-HT再摄取抑制活性，并且可以用作快速表达抗抑郁效果的抗抑郁药。
• Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020037907A1

  公开（公告）日：2002-03-28

  This invention provides compounds of Formula I having the structure 1 wherein A, B, Z, R and R 1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式1的化合物，其中A、B、Z、R和R1如前文所定义，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• New indolylpropanols, processes for their preparation and their use, and
  申请人：Beiersdorf AG

  公开号：US04935414A1

  公开（公告）日：1990-06-19

  Substituted indolylpropanols of the formula I ##STR1## in which R.sup.1 denotes a cyano, carboxamido, alkoxycarbonyl, hydroxyl or acetyl group, Y stands for the group A ##STR2## wherein n is the number 2 or 3, or the group B, ##STR3## R.sup.2 stands for R.sup.2 ' where Y denotes the group A and for R.sup.2 " when Y denotes the group B, where R.sup.2 ' denotes pyridinyl, thienyl or substituted phenyl which is monosubstituted or disubstituted by difluoromethoxy, difluoromethylthio, trifluoromethoxy, trifluoromethylthio, trifluoroethoxy, alkoxyalkoxy, cycloalkylalkoxy, alkoxyalkyl, alkylthioalkoxy, alkylsulphinylalkoxy, alkylsulphonylalkoxy, alkoxyalkylthio, alkoxyalkylsulphinyl, alkoxyalkylsulphonyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl and dialkylaminoalkoxy, and R.sup.2 " denotes pyridinyl, thienyl, phenyl or substituted phenyl which is monosubstituted or disubstituted by halogen, alkyl, cycloalkyl, alkoxy, difluoromethoxy, difluoromethylthio, trifluoromethoxy, trifluoromethylthio, trifluoroethoxy, alkoxyalkoxy, cycloalkylalkoxy, alkoxyalkyl, alkylthioalkoxy, alkylsulphinylalkoxy, alkylsulphonylalkoxy, alkoxyalkylthio, alkoxyalkylsulphinyl, alkoxyalkylsulphonyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl and dialkylaminoalkoxy, and R.sup.3 stands for R.sup.3 ' when Y denotes the group A and for R.sup.3 " when R denotes the group B, where R.sup.3 ' denotes hydrogen, difluoromethoxy, difluoromethylthio, trifluoromethoxy, trifluoromethylthio, trifluoroethoxy, alkoxylalkoxy, alkoxyalkyl, alkylthioalkoxy, alkylsulphinylalkoxy, alkylsulphonylalkoxy, alkoxyalkylthio, alkoxyalkylsulphinyl, alkoxyalkylsulphonyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl or dialkylaminoalkoxy, and R.sup.3 " denotes hydrogen, alkoxy, halogen, difluoromethoxy, difluoromethylthio, trifluoromethoxy, trifluoromethylthio, trifluoroethoxy, alkoxyalkoxy, alkoxyalkyl, alkylthioalkoxy, alkylsulphinylalkoxy, alkylsulphonylalkoxy, alkoxyalkylthio, alkoxyalkylsulphinyl, alkoxyalkylsulphonyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl or dialkylaminoalkoxy, or a physiologically tolerable hydrolysable derivative thereof, in which the hydroxyl group in the 2-position of the 3-aminopropoxy side chain is present in esterified form, and also their tautomeric forms and their salts and also acid addition salts, where in all cases previously mentioned alkyl of the alkyl groups or of alkyl moieties or alkylene moieties of groups in each case denotes straight-chain or branched alkyl or alkylene having 1 to 6 carbon atoms and cycloalkyl has 3 to 7 carbon atoms, with the proviso that if R.sup.2 ' denotes pyridinyl or thienyl, R.sup.3 ' does not denote hydrogen, but one of the other R.sup.3 radicals mentioned show positive inotropic, vasodilatory and antiarrhythmic action and are suitable for the treatment of cardiac insufficiency, cardiac arrhythmias and hypertonia, coronary heart disease and peripheral and central arterial circulatory disturbances.

  化合物I的替代吲哚基丙醇，其中R.sup.1代表氰基、羧酰胺基、烷氧羰基、羟基或乙酰基，Y代表A组，其中n为数字2或3，或B组，R.sup.2代表R.sup.2'，其中Y代表A时，为R.sup.2"，其中Y代表B时，R.sup.2'代表吡啶基、噻吩基或被二氟甲氧基、二氟甲基硫基、三氟甲氧基、三氟甲基硫基、三氟乙氧基、烷氧基烷氧基、环烷烷氧基、烷氧基烷基、烷基硫氧基烷氧基、烷基亚砜氧基烷氧基、烷基砜氧基烷氧基、烷氧基烷基硫氧基、烷氧基烷基亚砜氧基、烷氧基烷基砜氧基、烷基硫氧基烷基、烷基亚砜氧基烷基、烷基砜氧基烷基和二烷基氨基烷氧基单取代或双取代的吡啶基、噻吩基或取代的苯基，R.sup.2"代表吡啶基、噻吩基、苯基或被卤素、烷基、环烷基、烷氧基、二氟甲氧基、二氟甲基硫基、三氟甲氧基、三氟甲基硫基、三氟乙氧基、烷氧基烷氧基、环烷烷氧基、烷氧基烷基、烷基硫氧基烷氧基、烷基亚砜氧基烷氧基、烷基砜氧基烷氧基、烷氧基烷基硫氧基、烷氧基烷基亚砜氧基、烷氧基烷基砜氧基、烷基硫氧基烷基、烷基亚砜氧基烷基、烷基砜氧基烷基和二烷基氨基烷氧基单取代或双取代的取代的苯基，R.sup.3代表R.sup.3'，当Y代表A时，为R.sup.3"，当R代表B时，R.sup.3'代表氢、二氟甲氧基、二氟甲基硫基、三氟甲氧基、三氟甲基硫基、三氟乙氧基、烷氧基烷氧基、烷氧基烷基、烷基硫氧基烷氧基、烷基亚砜氧基烷氧基、烷基砜氧基烷氧基、烷氧基烷基硫氧基、烷氧基烷基亚砜氧基、烷氧基烷基砜氧基、烷基硫氧基烷基、烷基亚砜氧基烷基、烷基砜氧基烷基或二烷基氨基烷氧基，R.sup.3"代表氢、烷氧基、卤素、二氟甲氧基、二氟甲基硫基、三氟甲氧基、三氟甲基硫基、三氟乙氧基、烷氧基烷氧基、烷氧基烷基、烷基硫氧基烷氧基、烷基亚砜氧基烷氧基、烷基砜氧基烷氧基、烷氧基烷基硫氧基、烷氧基烷基亚砜氧基、烷氧基烷基砜氧基、烷基硫氧基烷基、烷基亚砜氧基烷基、烷基砜氧基烷基或二烷基氨基烷氧基，或其生理上可耐受的水解衍生物，其中在3-氨基丙氧基侧链的2-位羟基以酯化形式存在，以及它们的互变异构体和盐以及酸加合物盐，在所有先前提到的情况下，所述烷基或各种基团的烷基或烷基或烷基亚烷基基团的碳原子数为1至6的直链或支链烷基或烷基，环烷基的碳原子数为3至7，但如果R.sup.2'代表吡啶基或噻吩基，R.sup.3'不代表氢，而是其他R.sup.3基团中的一个，表现出正向肌力作用、扩血管作用和抗心律失常作用，适用于治疗心脏功能不全、心律失常和高血压、冠心病以及周围和中央动脉循环障碍。
• Selective beta3 adrenergic agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0764640A1

  公开（公告）日：1997-03-26

  The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

  本发明属于医学领域，特别是在治疗2型糖尿病和肥胖方面。更具体地说，本发明涉及对选择性β3肾上腺素能受体激动剂在治疗2型糖尿病和肥胖方面的应用。该发明提供了化合物和治疗2型糖尿病的方法，包括向需要的哺乳动物施用具有I和II式的化合物。